Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2016 Update
|出版商||La Merie Publishing||商品編碼||358307|
|出版日期||內容資訊||英文 46 Pages
|競爭企業分析:Avastin、Cyramza、Eylea、Lucentis的抗VEGF/R生技仿製藥及 Bio-Superior Competitor Analysis: Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - 2016 Update|
|出版日期: 2016年02月29日||內容資訊: 英文 46 Pages||
以血管內皮層生長因子 (VEGF) 或VEGF受體 (VEGF-R) 為標的治療抗體，2015年整體銷售額為150億美元，是極為成功的產品類別。Avastin是多年的生技藥品暢銷者，不過，視網膜疾病治療用的抗VEGF產品，Lucentis、Eylea，2015年第一次記錄了比癌症治療用的抗VEGF/R產品高的銷售額。
本報告提供各種癌症的症狀、視網膜疾病的治療所採用的血管內皮層生長因子 (VEGF) 此外關於以其受體 (VEGF-R) 為標的之重組抗體領域中的競爭產品評價，在各產品的銷售額、症狀的組合、開發平台，標的抗體、蛋白質的開發中現在進行中的計劃相關資訊等。
The Competitive Intelligence Report "Anti-VEGF/R Biosimilars and Biosuperiors of Avastin, Cyramza, Eylea and Lucentis - a 2016 Update " provides a competitor evaluation in the field of recombinant antibodies targeting vascular endothelial growth factor (VEGF) or its receptors (VEGF-R) for treatment of a variety of cancer indications and retinal diseases as of February 2016. Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report.
Therapeutic antibodies targeting vascular endothelial growth factor (VEGF) or VEGF receptor (VEGF-R) are a highly successful class of products as evidenced by total sales of US$ 15 bln in 2015. While Avastin has been known for years as a blockbuster biologic, anti-VEGF products Lucentis and Eylea for treatment of retinal diseases posted for the first time in 2015 higher sales than the anti-VEGF/R products for cancer treatment. The commercial success of Avastin as a single product approved for many cancer indications and the forthcoming patent expiries in the major markets have attracted a number of biosimilar developments in advanced clinical stages.
Until now, less attention has been paid to anti-VEGF antibodies used for treatment of ophthalmic diseases although the approved antibody products are attractive targets for the second wave of biosimilar antibodies because of the impressive market growth fueled by the clinical success and patent expiries in the mid-term.
The report includes a compilation of currently active projects in development of VEGF and VEGF-R targeting antibodies or proteins for treatment of cancer and neo-angiogenic eye diseases. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.